JP2019518738A - 組成物、ならびにその適用および薬学的調製の方法 - Google Patents

組成物、ならびにその適用および薬学的調製の方法 Download PDF

Info

Publication number
JP2019518738A
JP2019518738A JP2018559306A JP2018559306A JP2019518738A JP 2019518738 A JP2019518738 A JP 2019518738A JP 2018559306 A JP2018559306 A JP 2018559306A JP 2018559306 A JP2018559306 A JP 2018559306A JP 2019518738 A JP2019518738 A JP 2019518738A
Authority
JP
Japan
Prior art keywords
acid
acceptable ester
composition according
disease
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018559306A
Other languages
English (en)
Japanese (ja)
Inventor
リーピン リュー
リーピン リュー
Original Assignee
シンセン ハイタイド バイオファーマシューティカル リミテッド
シンセン ハイタイド バイオファーマシューティカル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンセン ハイタイド バイオファーマシューティカル リミテッド, シンセン ハイタイド バイオファーマシューティカル リミテッド filed Critical シンセン ハイタイド バイオファーマシューティカル リミテッド
Priority claimed from PCT/CN2016/105294 external-priority patent/WO2017193563A1/zh
Publication of JP2019518738A publication Critical patent/JP2019518738A/ja
Priority to JP2021180724A priority Critical patent/JP7448511B2/ja
Priority to JP2023189115A priority patent/JP7668859B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018559306A 2015-11-13 2016-11-10 組成物、ならびにその適用および薬学的調製の方法 Pending JP2019518738A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021180724A JP7448511B2 (ja) 2015-11-13 2021-11-05 組成物、ならびにその適用および薬学的調製の方法
JP2023189115A JP7668859B2 (ja) 2015-11-13 2023-11-06 組成物、ならびにその適用および薬学的調製の方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562254739P 2015-11-13 2015-11-13
CN201610303976.5A CN106692973A (zh) 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂
CN201610303976.5 2016-05-10
PCT/CN2016/105294 WO2017193563A1 (zh) 2015-11-13 2016-11-10 一种组合物及其用途、药物制剂

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021180724A Division JP7448511B2 (ja) 2015-11-13 2021-11-05 組成物、ならびにその適用および薬学的調製の方法

Publications (1)

Publication Number Publication Date
JP2019518738A true JP2019518738A (ja) 2019-07-04

Family

ID=58939703

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018559306A Pending JP2019518738A (ja) 2015-11-13 2016-11-10 組成物、ならびにその適用および薬学的調製の方法
JP2021180724A Active JP7448511B2 (ja) 2015-11-13 2021-11-05 組成物、ならびにその適用および薬学的調製の方法
JP2023189115A Active JP7668859B2 (ja) 2015-11-13 2023-11-06 組成物、ならびにその適用および薬学的調製の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021180724A Active JP7448511B2 (ja) 2015-11-13 2021-11-05 組成物、ならびにその適用および薬学的調製の方法
JP2023189115A Active JP7668859B2 (ja) 2015-11-13 2023-11-06 組成物、ならびにその適用および薬学的調製の方法

Country Status (5)

Country Link
US (3) US20170135995A1 (https=)
JP (3) JP2019518738A (https=)
KR (1) KR102892545B1 (https=)
CN (2) CN106692973A (https=)
IL (2) IL300237A (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102600891B1 (ko) * 2017-08-11 2023-11-13 센젠 하이타이드 바이오파마슈티컬 리미티드 염증성 장 질환의 치료를 위한 방법 및 조성물
ES2645028B2 (es) * 2017-10-13 2018-06-04 Maria D. GÓMEZ GARRE Preparación farmacéutica única y estable que contiene berberina, en formulación de liberación lenta, una estatina y ubiquinol para el tratamiento de la enfermedad cardiovascular y los factores de riesgo asociados
CN108042522A (zh) * 2017-12-29 2018-05-18 广东海洋大学 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用
CN108159037A (zh) * 2017-12-29 2018-06-15 广东海洋大学 一种用于提高神经保护功能的不饱和脂肪酸组合物及其应用
CN111499626A (zh) * 2019-01-31 2020-08-07 西南大学 一种表小檗碱的合成方法及应用
WO2024245370A1 (zh) * 2023-05-31 2024-12-05 上海复宏汉霖生物技术股份有限公司 一种组合产品、盐及其用途
WO2026006683A1 (en) * 2024-06-28 2026-01-02 Wisteria Therapeutics, Inc. Omega-7 fatty acid berberine salt and methods of uses thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090289A1 (en) * 2006-02-09 2007-08-16 National Research Council Of Canada Combinations of botanical extracts for promoting cardiovascular health
US20080306154A1 (en) * 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
WO2009028457A1 (ja) * 2007-08-29 2009-03-05 Shinshu University 非アルコール性脂肪肝炎治療薬
WO2010104595A1 (en) * 2009-03-11 2010-09-16 Xintria Pharmaceutical Corporation, Inc. Methods and compositions for the treatment of metabolic and cardiovascular disorders
CN101879162A (zh) * 2010-02-23 2010-11-10 江苏格林生物科技有限公司 一种α-亚麻酸乙酯配伍小檗碱的减肥物
US20130040913A1 (en) * 2011-02-16 2013-02-14 Pivotal Therapeutics Inc. Omega 3 fatty acidfor use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (cvd) who are deficient in blood epa and dha levels
WO2014143272A1 (en) * 2013-03-13 2014-09-18 Matinas Biopharma Inc. Omega-3 pentaenoic acid compositions and methods of use
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
WO2015034984A1 (en) * 2013-09-05 2015-03-12 Emory University Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto
WO2016015634A1 (en) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
WO2016057915A1 (en) * 2014-10-10 2016-04-14 Sancilio & Company, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196515A1 (en) * 2006-02-22 2007-08-23 Kothari Shil C Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome X
WO2008134828A2 (en) * 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
ES2530049T3 (es) * 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
CA2827561A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
CN102580087B (zh) * 2012-03-08 2013-08-21 董萍 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
JP6359517B2 (ja) * 2012-03-30 2018-07-18 サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. ω−３脂肪酸エステル組成物
US8652518B2 (en) * 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
US9446100B2 (en) * 2015-02-13 2016-09-20 Eastern Vision Limited Dietary supplements and formulations

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090289A1 (en) * 2006-02-09 2007-08-16 National Research Council Of Canada Combinations of botanical extracts for promoting cardiovascular health
US20080306154A1 (en) * 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
WO2009028457A1 (ja) * 2007-08-29 2009-03-05 Shinshu University 非アルコール性脂肪肝炎治療薬
WO2010104595A1 (en) * 2009-03-11 2010-09-16 Xintria Pharmaceutical Corporation, Inc. Methods and compositions for the treatment of metabolic and cardiovascular disorders
CN101879162A (zh) * 2010-02-23 2010-11-10 江苏格林生物科技有限公司 一种α-亚麻酸乙酯配伍小檗碱的减肥物
US20130040913A1 (en) * 2011-02-16 2013-02-14 Pivotal Therapeutics Inc. Omega 3 fatty acidfor use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (cvd) who are deficient in blood epa and dha levels
WO2014143272A1 (en) * 2013-03-13 2014-09-18 Matinas Biopharma Inc. Omega-3 pentaenoic acid compositions and methods of use
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
WO2015034984A1 (en) * 2013-09-05 2015-03-12 Emory University Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto
WO2016015634A1 (en) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
WO2016057915A1 (en) * 2014-10-10 2016-04-14 Sancilio & Company, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states

Also Published As

Publication number Publication date
KR20230019269A (ko) 2023-02-08
US20170135995A1 (en) 2017-05-18
JP2022017496A (ja) 2022-01-25
IL300237A (en) 2023-03-01
IL262929B2 (en) 2023-07-01
US11369573B2 (en) 2022-06-28
CN106692973A (zh) 2017-05-24
US20200405646A1 (en) 2020-12-31
US11883539B2 (en) 2024-01-30
JP7448511B2 (ja) 2024-03-12
IL262929A (en) 2018-12-31
IL262929B1 (en) 2023-03-01
JP7668859B2 (ja) 2025-04-25
JP2024014894A (ja) 2024-02-01
CN116492339A (zh) 2023-07-28
KR102892545B1 (ko) 2025-12-09
US20220296528A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
JP7668859B2 (ja) 組成物、ならびにその適用および薬学的調製の方法
JP7285903B2 (ja) ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法
AU2023200123B2 (en) Composition, and application and pharmaceutical preparation thereof
US20230348457A1 (en) Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201110

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210707